Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension. Article - Février 2012

Jean-Marie Launay, Philippe Hervé, Jacques Callebert, Ziad Mallat, Corinne Collet, Stéphane Doly, Arnauld Belmer, Silvina Diaz, Sarah Hatia, Francine Côté, Marc Humbert, Luc Maroteaux

Jean-Marie Launay, Philippe Hervé, Jacques Callebert, Ziad Mallat, Corinne Collet, Stéphane Doly, Arnauld Belmer, Silvina Diaz, Sarah Hatia, Francine Côté, Marc Humbert, Luc Maroteaux, « Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension.  », Blood, février 2012, pp. 1772-80. ISSN 0006-4971

Abstract

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by lung endothelial dysfunction and vascular remodeling. Recently, bone marrow progenitor cells have been localized to PAH lungs, raising the question of their role in disease progression. Independently, serotonin (5-HT) and its receptors have been identified as contributors to the PAH pathogenesis. We hypothesized that 1 of these receptors, 5-HT(2B), is involved in bone marrow stem cell mobilization that participates in the development of PAH and pulmonary vascular remodeling. A first study revealed expression of 5-HT(2B) receptors by circulating c-kit(+) precursor cells, whereas mice lacking 5-HT(2B) receptors showed alterations in platelets and monocyte-macrophage numbers, and in myeloid lineages of bone marrow. Strikingly, mice with restricted expression of 5-HT(2B) receptors in bone marrow cells developed hypoxia or monocrotaline-induced increase in pulmonary pressure and vascular remodeling, whereas restricted elimination of 5-HT(2B) receptors on bone marrow cells confers a complete resistance. Moreover, ex vivo culture of human CD34(+) or mice c-kit(+) progenitor cells in the presence of a 5-HT(2B) receptor antagonist resulted in altered myeloid differentiation potential. Thus, we demonstrate that activation of 5-HT(2B) receptors on bone marrow lineage progenitors is critical for the development of PAH.

Voir la notice complète sur HAL

Actualités